標題：維妥組單抗，Veltuzumab，CAS:728917-18-8， AntibodySystem Laboratories
貨號：DHC90711
http://www.atagenix.com/product_detail-75427.html
別名：hA20 / IMMU-106, CAS: 728917-18-8
簡介：
Veltuzumab (IMMU-106) 是一種人源化抗 CD20 單克隆抗體。Veltuzumab 在 Daudi 細胞系中的 EC50 值較低，為 0.08-0.09 μg/mL。Veltuzumab 可用于癌癥的研究，如非霍奇金淋巴瘤 (NHL)。
形態(tài)：Liquid
保存：0.01M PBS, pH 7.4.
濃度：1 mg/ml
純度：>95%
克隆性：Monoclonal
亞型：IgG1-kappa
應用：Research Grade Biosimilar
靶點：hA20 / IMMU-106
應用范圍：類似物，陽性對照抗體
產(chǎn)地：France
標記物：Unconjugate
品牌：AntibodySystem
抗原來源：Mammalian cells
適應物種：Human
標識物：Unconjugate
保存條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -336°C long term.
參考文獻：
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. PMID: 20214444
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. PMID: 28983798
Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders. PMID: 35185862
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? PMID: 28765121
Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. PMID: 25133328
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. PMID: 18941114
Immunotherapy in indolent Non-Hodgkin's Lymphoma. PMID: 35663281
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. PMID: 21173095
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. PMID: 23829485
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. PMID: 19451441
Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. PMID: 19330725
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia. PMID: 26389849
Bullous Diseases. PMID: 29131038
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. PMID: 27515248
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line. PMID: 24386925
Rituximab resistance. PMID: 21658619
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. PMID: 25847298
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). PMID: 18829494
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. PMID: 25150258
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. PMID: 19223402
Treatment Update of Autoimmune Blistering Diseases. PMID: 30850044
B-cell depletion in immune thrombocytopenia. PMID: 23664523
Emerging immunological drugs for chronic lymphocytic leukemia. PMID: 26153226
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. PMID: 21090841
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. PMID: 19710501
Novel agents for chronic lymphocytic leukemia. PMID: 23680477
Epitope Mapping of Rituximab Using HisMAP Method. PMID: 35225667
CD20-targeted therapy: the next generation of antibodies. PMID: 20350667
Future therapies for pemphigus vulgaris: Rituximab and beyond. PMID: 26792592
Novel CD20 monoclonal antibodies for lymphoma therapy. PMID: 23057966
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. PMID: 20628151
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. PMID: 25249370
Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus. PMID: 24841238
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. PMID: 20425465
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. PMID: 22039078
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. PMID: 28499646
[Novel B-cell directed strategies for the treatment of rheumatic diseases]. PMID: 19513729
The future of CD20 monoclonal antibody therapy in B-cell malignancies. PMID: 20367564
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties. PMID: 23116517
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. PMID: 18922911
Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development. PMID: 21105187
Shifting Focus in the Therapeutics of Immunobullous Disease. PMID: 28584371
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. PMID: 18025153
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. PMID: 29143151
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. PMID: 19372261
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. PMID: 22271448
Complicated Diagnosis and Treatment of HA20 due to Contiguous Gene Deletions involving 6q23.3. PMID: 34032947
Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides. PMID: 20127947
Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia. PMID: 19562616
A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. PMID: 20876805
Hepatocyte paraffin 1 immunoexpression in esophageal brush samples. PMID: 15918175
Three different B-cell depletion (anti-CD20 monoclonal antibodies) treatments for severe resistant systemic lupus erythematosus. PMID: 20534646
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells. PMID: 23696859
Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. PMID: 15815716
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. PMID: 15102696
